Methemoglobinemia is a life-threatening condition that can be congenital or acquired. It is characterized by the inability of haemoglobin to carry oxygen because the ferrous part of the heme molecule has been oxidized to ferric state. Acquired methemoglobinemia is due to medication or chemicals that cause the rate of methemoglobin formation to exceed its rate of reduction. We performed a search of American National library of Medicine (PubMed) with the following key word "Acquired Methemoglobinemia". Two hundred forty-two episodes (40.1% published in year 2000 or after) were found. A retrospective case series was found. In which it describes the cases of acquired methemoglobinemia detected and the clinical circumstances under which they occurred at two tertiary care hospitals and affiliated outpatient clinics over 28 months. One hundred thirty-eight cases of acquired methemoglobinemia were detected over 28 months. There were no gender predisposition and performed over a wide range of age (Patient aged 4 days to 86 years). Signs and symptoms of acquired methemoglobinemia usually occur within 20-30 min of drug administration. One of first sign is cyanosis. Early symptoms include anxiousness and dizziness, with fatigue and confusion. The diagnosis of methemoglobinemia is based on clinical assessment when respiratory status does not explain the cyanosis that a patient has and is refractory to oxygen therapy. As management of methemoglobinemia depends on precise detection, clinicians who administer or prescribe oxidizing agent must be aware of clinical symptoms of methemoglobinemia. Methylene blue is currently the drug of choice for the management of methemoglobinemia.
INTRODUCTION
Methemoglobin is the oxidized form of haemoglobin, which does not bind oxygen and increases the affinity of oxygen for the partially oxidized portion of haemoglobin. Increased levels of methemoglobin in the blood are secondary to congenital changes or exposure to several drugs, chemical agents, or food items resulting in a disorder with cyanosis. It can lead to death if not treated. 1
Normal Physiology
The principle function of haemoglobin is to deliver oxygen from lungs to tissue cells, depending upon the variable affinity that haemoglobin has for oxygen. This affinity is principally dependent on the local partial pressure of oxygen (pO 2 ), but pH, partial pressure of carbon dioxide (pCO 2 ), concentration of organic phosphates are also significant. Local conditions in the lungs (relatively high pO 2 , low pCO 2 , etc.) are associated with high affinity, so that haemoglobin readily binds oxygen here; the product of this binding is oxyhaemoglobin. By contrast in the microvasculature of the tissue, local condition (relatively low pO 2 , high pCO 2 , etc.) are associated with low haemoglobin affinity for oxygen and oxy haemoglobin readily dissociates, releasing oxygen to tissue cells.
Haemoglobin and Methemoglobin
The adult haemoglobin comprises four folded polypeptide chains (two alphas and two betas), each of which has a porphyrin heme group attached. 2 At the centre of each of the four heme group is an atom of iron in the ferrous (Fe 2+ ) state. These four iron atoms are the functional centres of haemoglobin molecule because it is here that oxygen reversibly binds to form oxyhemoglobin. 3 The only difference between haemoglobin and methemoglobin is that one or more of the four iron atoms in methemoglobin molecule are in ferric (Fe 3+ ) state rather than ferrous (Fe 2+ ) state and are therefore incapable of binding oxygen. 4 Conversion of iron from the ferrous to ferric state represents loss of an electron, i.e. it is an oxidative process. 5 When the haemoglobin, Hgb(Fe(II))O2, is auto-oxidized to methemoglobin, Hgb(Fe(III)), the methemoglobin, is recycled back to haemoglobin Hgb(Fe(II)) so that in the steady state the amount of intracellular methemoglobin is <1%. The methemoglobin is reduced by the NADHcytochrome b5-metHgb reductase. In addition, reduction can be done by several alternative pathways such as NADPH-dependent MetHgb reductase and direct reduction by intracellular ascorbate and glutathione. 6 ( Figure 1 )
Epidemiology

United States
Hereditary methemoglobinemia is a rare condition. This enzymatic deficiency is endemic in certain Native American tribes (Navajo and Athabascan Alaskans).
International
Methemoglobinemia occurs rarely throughout the world. Cytochrome b5 reductase deficiency (type Ib5R) is also endemic in the Yakutsk people of Siberia.
Race
The congenital form of methemoglobinemia due to cytochrome b5 reductase deficiency (type Ib5R) is endemic in certain ethnic groups. These groups include the Navajo, Athabascan Alaskans and the Yakutsk people in Siberia.
Sex
No difference exists in disease occurrence of acquired methemoglobinemia between males and females.
Age
Infants (especially premature infants) are more susceptible to the development of methemoglobinemia after drug or toxin exposure. This is because infants have significantly lower levels of cytochrome b5 reductase.
Indian Perspective
• In India, methemoglobinemia is not very common, which may be due to lack of awareness or lack of epidemiological studies on the disease. • Groundwater is a major source of drinking water in rural Karnataka. 
Clinical Features and Pathophysiology
Symptoms are proportional to the fraction of methemoglobin. A normal methemoglobin fraction is about 1% (range, 0-3%). pathway, a second enzymatic system which reduces methemoglobin to haemoglobin, is directly dependent on both the activity of glutathione and glucose-6-phosphate dehydrogenase). However hereditary deficiencies in the activity of this enzyme result in chronic methemoglobin levels of 40% to 50%. Methemoglobin is formed by oxidation of the ferrous iron (Fe (2+)) of haemoglobin to ferric (Fe (3+)) form by oxidizing chemical or drugs this reaction impairs the ability of haemoglobin to transport oxygen and carbon dioxide, leading to tissue hypoxemia and in severe cases, death. 10
Aetiology
Congenital (hereditary) methemoglobinemia
Hereditary methemoglobinemia may be divided into two categories as follows: 5
• Methemoglobinemia due to an altered form of haemoglobin (i.e., Hb M) • Methemoglobinemia due to an enzyme deficiency (NADH reductase deficiency) that decreases the rate of reduction of iron in the haemoglobin molecule Several variants of haemoglobin M have been described, including Hb Ms, Hb M Iwate , Hb M Boston , Hb M Hyde Park and Hb M Saskatoon . These are usually autosomal dominant in nature. Alpha-chain substitutions cause cyanosis at birth, whereas the effects of beta-chain substitutions become clinically apparent in infants at 4-6 months of age.
There are four types of hereditary methemoglobinemia that are secondary to deficiency of NADH cytochrome b5 reductase, which is encoded by the CYB5R3gene. All of them are autosomal recessive disorders. Heterozygotes have 50% enzyme activity and no cyanosis; homozygotes that have elevated methemoglobin levels above 1.5% have clinical cyanosis. The four types are as follows:
• Type I -This is the most common variant and the enzyme deficiency is limited to the erythrocytes causing cyanosis; cyanosis usually, but not always, develops during infancy. 11 • Type II -Widespread deficiency of the enzyme occurs in various tissues, including erythrocytes, liver, fibroblasts and brain; it is associated with severe CNS symptoms, including encephalopathy, microcephaly, hypertonia, athetosis, opisthotonos, strabismus, mental retardation and growth retardation; cyanosis is evident at an early age. • Type III -Although the hematopoietic system (platelets, RBCs and white blood cells [WBCs]) is involved, the only clinical consequence is cyanosis. • Type IV -Like type I, this type has isolated involvement of the erythrocytes but results in chronic cyanosis. Deficiency of NADPH-flavin reductase can also cause methemoglobinemia.
Acquried Methmolobinemia
The Hgb(Fe(II))O 2 methemoglobin Hgb(Fe(III)) couple can undertake redox transformations under a number of important biological situations and it is no surprise that xenobiotic are substrates, forming methemoglobin in the process. The acquired formation of methemoglobin can have consequences. While Hgb(Fe(II)) can be oxidized directly by some xenobiotic to form methemoglobin, resulting in the reduction of the xenobiotic, the usual reaction is the oxidation of the xenobiotic by Hgb(Fe(II)) O 2 , resulting in H 2 O and methemoglobin. 6 There are two basic mechanisms for acquired methemoglobinemia: direct or indirect oxidation of the haemoglobin. Rarely the Fe(II) in haemoglobin, Hgb(Fe(II)), can be directly oxidized to Fe(III) to form methemoglobin. Direct oxidation can be caused by chlorates, hexavalent chromates, cobalt and copper II salts. 12 Indirect oxidation is more prevalent. Oxidation occurs with participation of both the iron and the oxygen, with superoxide and hydrogen peroxide production when the haemoglobin bound oxygen accepts electrons from ferrous iron. 13 Aniline is a potent inducer of methemoglobinemia and haemolysis, but is converted first to phenylhydroxylamine that is oxidized to nitrosobenzyene by Hgb(Fe(II)) and oxygen. Figure 2 The nitrosobenzene is subsequently reduced by a NADPH flavin reductase back to aniline, using NADPH derived from glucose-6-phoshate dehydrogenase and the hexose monophosphate shunt. 14 Alternatively, glutathione can be used as a source of reducing power. 15, 16 Aniline and nitros-derivatives are transformed into phenylhydroxylamines by hepatic mixed function oxidases and then can become inducers of methemoglobin. 17 Such bioactivation is important for the toxic effects of dapsone and sulfamethoxazole (the sulfa component in trimethoprim-sulfamethoxazole, Septra, or Bactrim), probably via the formation of hydroxylamines. The dapsone hydroxylamine was the more potent in forming methemoglobin and consuming glutathione compared to the sulfamethoxazole hydroxyl amine, paralleling the in vivo findings. 18 Drugs that induce Methemoglobinemia.
Evaluation
Investigations
Medical Group Drugs
Analgesic and Antipyretics test for determining whether dark blood is due to methemoglobinemia is to bubble 100% oxygen in a tube that contains the dark blood. Blood that remains dark likely does so because of the presence of methemoglobin.
Another simple test (and one that is less likely to splash potentially infectious blood) is to place 1-2 drops of blood on white filter paper, then evaluate for colour change upon exposure to oxygen. (This test can be accelerated by gently blowing supplemental oxygen onto the filter paper.) Deoxygenated haemoglobin changes from dark red or violet to bright red, whereas methemoglobin remains brown.
Serum levels of nitrites or other offending drugs may be determined. Often, these results are not immediately available and treatment may have to be started empirically if the index of suspicion is high.
Arterial Blood Gas Determination
The presence of methemoglobin can falsely elevate the calculated oxygen saturation when Arterial Blood Gases (ABGs) are obtained. One possible clue to the diagnosis of methemoglobinemia is the presence of a "saturation gap." This occurs when there is a difference between the oxygen saturation measured on pulse oximetry and the oxygen saturation calculated on the basis of ABG results.
The partial Pressure of Oxygen (PO 2 ) value of the ABG measurement reflects plasma oxygen content and does not correspond to the oxygen-carrying capacity of haemoglobin. It should be within the reference range in patients with methemoglobinemia.
Oximetry
Co-oximetry
Co-oximetry should be performed if available. The co-oximeter is an accurate device for measuring methemoglobin and is the key to diagnosing methemoglobinemia. It is a simplified spectrophotometer that can measure the relative absorbance of 4 different wavelengths of light and thus is capable of differentiating methemoglobin from carboxyhemoglobin, oxyhemoglobin and deoxyhemoglobin. Newer co-oximeter can also measure sulfhemoglobin, which can be confused with methemoglobin by older devices.
Availability of appropriate equipment may be a problem. Lipemic specimens may result in a falsely elevated methemoglobin level. In addition, the presence of methylene blue interferes with the accurate measurement of methemoglobin by co-oximetry, hence this method cannot be used to monitor methemoglobin levels after treatment with methylene blue is initiated. Blood substitutes can cause co-oximetry to yield unreliable results.
Pulse oximetry
Pulse oximetry is used extensively in the evaluation of patients with cyanosis and respiratory distress. Findings of bedside pulse oximetry in the presence of methemoglobinemia may be misleading. Pulse oximetry measurements with low-levels of methemoglobinemia often result in falsely low values for oxygen saturation and are often falsely high in those with high-level methemoglobinemia. The reason for these inaccuracies is as follows.
The pulse oximeter only measures the relative absorbance of 2 wavelengths of light (660 nm and 940 nm) to differentiate oxyhemoglobin from deoxyhemoglobin. The ratio of absorption of light at each of these wavelengths is converted into oxygen saturation by using calibration curves. Methemoglobin increases absorption of light at both wavelengths (more at 940 nm) and therefore offers optical interference to pulse oximetry by falsely absorbing light.
As a result, oxygen saturations by pulse oximetry in methemoglobinemia plateau at about 85%; therefore, a patient with a methemoglobin level of 5% and a patient with a level of 40% have approximately the same saturation values on pulse oximetry (~85%). The severity of the cyanosis does not correspond to the pulse oximetry reading: A patient may appear extremely cyanotic but still have a pulse oximetry reading in the high 80s.
Treatment
Early clinical recognition of methemoglobinemia is paramount, as patients often have only vague, nonspecific complaints, especially in the initial phase. High levels of methemoglobinemia can be life-threatening and necessitate emergency therapy. Treatment is advisable for patients with acute exposure to an oxidizing agent who have methemoglobin levels of 20% or higher. Patients with significant comorbidities (eg, Coronary Artery Disease [CAD] or anaemia) may require therapeutic intervention at lower methemoglobin levels (eg, 10%), especially if end-organ dysfunction (eg, cardiac ischemia) is present. If methemoglobinemia is the result of toxin exposure, then removal of this toxin is imperative. Further ingestion or administration of the drug or chemical should be avoided.
Pharmacologic Therapy, Exchange Transfusion and Hyperbaric Oxygen
Methylene blue is the primary emergency treatment for documented symptomatic methemoglobinemia. It is given in a dose of 1-2 mg/kg (up to a total of 50 mg in adults, adolescents and older children) as a 1% solution in IV saline over 3-5 min. Administration may be repeated at 1 mg/kg every 30 min as necessary to control symptoms. Methylene blue is itself an oxidant at doses greater than 7 mg/kg and thus may cause methemoglobinemia in susceptible patients; hence, careful administration is essential.
Methylene blue is contraindicated in patients with G6PD deficiency. Because it requires G6PD to work, it is ineffective in G6PD-deficient patients with methemoglobinemia. Additionally, methylene blue administration may cause haemolysis in these patients.
Methylene blue is also not effective in patients with haemoglobin M (HbM). Other conditions in which methylene blue may be ineffective or even deleterious include Nicotinamide Adenine Dinucleotide Phosphate (NADPH) methemoglobin reductase (i.e., diaphorase II) deficiency and sulfhemoglobinemia.
Exchange transfusion (which replaces abnormal haemoglobin with normal haemoglobin) may be considered for G6PD-deficient patients who are severely symptomatic or unresponsive to methylene blue. Patients who are on long-acting medication (eg, dapsone) may have initial treatment success with subsequent relapse of symptoms. Gastric lavage followed by charcoal administration may decrease this prolonged drug effect. These patients should be monitored closely and retreated with methylene blue as necessary.
Hyperbaric oxygen treatment is another option for situations where methylene blue therapy is ineffective or contraindicated. This approach permits tissue oxygenation to occur through oxygen dissolved in plasma, rather than through haemoglobin-bound oxygen.
Infants with methemoglobinemia due to metabolic acidosis should be treated with IV hydration and bicarbonate to reverse the acidosis. The NADPHdependent methemoglobin reductase enzyme system requires glucose for the clearance of methemoglobin. Therefore, IV hydration with Dextrose 5% in Water (D5W) is often effective.
Patients with mild chronic methemoglobinemia due to enzyme deficiencies may be treated with oral medications in an attempt to decrease cyanosis. These medications include methylene blue, ascorbic acid and riboflavin. The methylene blue dosage in this setting is 100-300 mg/day, which may turn the urine blue in colour. The ascorbic acid dosage is 200-500 mg/day; unfortunately, long-term oral ascorbic acid therapy can cause the formation of sodium oxalate stones. The riboflavin dosage is 20 mg/day. Cimetidine can be used in dapsone-induced methemoglobinemia to prevent further formation of its metabolite. N-acetyl cysteine has been shown to reduce methemoglobin in some studies but is not currently an approved treatment for methemoglobinemia.
No pharmacologic treatment exists for hereditary forms of methemoglobinemia.
CASE REPORTS
Case 1:
A 16 year old boy was admitted in emergency department, after he had collapsed after a dental extraction in which Prilocaine hydrochloride 3% was used as topical anaesthesia. The patient is deeply cyanosed despite a good respiratory effort, a clear airway and bilateral breath sounds. Oxygen saturation is 60% with patient breathing in room air. Assisted ventilation started, cyanosis didn't improved. The attending consultant is alert for the possibility of methemoglobinemia. A blood specimen is drawn and the test results confirm the diagnosis of methehemoglobinemia. 19
Case 2:
A boy aged 18 months came to paediatric emergency, suspected as unknown poisoning. He has a history of vomiting, excessive irritability and seizure. After examination, it was found child has severe cyanosis, oxyhemoglobin saturation (SpO 2 ) to be only 86%.
His blood was chocolate brown in colour. His PaO 2 was 265mmHg. In view of high PaO 2 and low SpO 2 , methemoglobinemia was suspected. Arterial blood gas analysis with co-oximetry showed methemoglobin to be 39%. This confirmed methemoglobinemia. 20
Case 3:
A 39 year old woman who had a small bowel obstruction after resection of an appendical carcinoid tumour was given benzocaine topical spray for retropharyngeal discomfort. Within few minutes, she became ashen, dyspnoea and tachypeanic with an oxygen saturation of 73%. In the arterial blood gas values: Partial pressure of oxygen 507mmHg, methemoglobin level 48.2% and oxyhemoglobin level 51.3% was found. This lead to the diagnosis of acquired methemoglobinemia. 21
Case 4:
A 69-year-old white female patient weighing 175lb came for a transesophageal echocardiogram to assist in the evaluation of intracardiac thrombus. The patient had a history of ischemic heart disease, post coronary artery bypass, hypertension, post-menopausal hyperlipidaemia, type 2 diabetes mellitus, obesity and symptomatic atrial fibrillation. The patient was apparently taking the following medication: Amiodarone, aspirin, enoxaparin, glyburide, levothyroxine, metoprolol succinate, niacin, rabeprazole sodium and simvastatin and warfarin sodium. During transesophageal echocardiogram, the patient oxygen saturation level was measured at 90% by room air pulse oximetry so the oxygen level was adjusted. Results from the procedure were with in normal limits, so the cardio version was completed and was successful and benzocaine spray was applied orally. After 15 min post procedure, patient developed central cyanosis and oxygen saturation level suddenly decreased to 70%. Methemoglobinemia was suspected and then confirmed by arterial blood gasses obtained, where PaO 2 was 293 and methemoglobin was 41.1%. 22
Case 5:
A 52-year-old man with squamous cell cancer of the retro molar trigone region was scheduled for a radical neck dissection and partial mandibuloctomy. Because of concern to intubate this patient, a topical 2% viscous Lidocaine 5ml, followed by two 1sec spray of Cetacaine (14% benzocaine, 2% tetracaine and other ingredient). Laryngoscopy correctly predicted an easy intubation and thus induced anaesthesia in a routine intravenous manner. Over the next hour the pulse oximeter displayed a progressive in oxygen saturation from 99% to 94% and eventually to mid-80s after 3hrs. Arterial blood gas revealed 26% methemoglobin. And patient is diagnosed with methemoglobinemia. 23
CONCLUSION
Methemoglobin is a useless form of haemoglobin, which is constantly being formed in red blood cells of peripheral blood. However, due to the effect of enzyme reducing system that converts methemoglobin to haemoglobin, concentration remains low in health. Increased level of methemoglobin, termed methemoglobinemia, reducing oxygenation of tissue cells, causing cyanosis. Severe methemoglobinemia (methemoglobin> 70% of total haemoglobin) is potentially fatal. A drug rarely produce methemoglobinemia when given in recommended dose to normal persons but acquire methemoglobinemia appears to be relatively common in infants within three months and patients with congenital deficiencies following exposed to oxidants drugs. Monitoring of methemoglobin levels suggested in patient with high risk of methemoglobinemia.
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